Lynparza (olaparib) receives a positive recommendation from NICE for maintenance treatment of BRCA-mutated relapsed, platinum-sensitive high-grade ovarian, fallopian tube or peritoneal cancer

Lynparza (olaparib) receives a positive recommendation from NICE for maintenance treatment of BRCA-mutated relapsed, platinum-sensitive high-grade ovarian, fallopian tube or peritoneal cancer

Following today’s decision from the National Institute for Health and Care Excellence (NICE) to recommend Lynparza (olaparib) for the maintenance treatment of BRCA-mutated relapsed, platinum-sensitive, high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer, following 2 or more courses of platinum-based chemotherapy, please see below for commentary from AstraZeneca UK and MSD spokespeople. 1

Tom Keith-Roach, President, AstraZeneca UK, said: “Olaparib was discovered and developed in the UK, which makes today’s positive recommendation for BRCA-mutated platinum-sensitive relapsed, high-grade epithelial ovarian cancer patients in the UK even more significant. AstraZeneca has a bold ambition to provide hope for patients with cancer. This requires continued investment and greater access to new innovations, and today’s news is another positive step.”

David Long, Head of Oncology at MSD UK said: “BRCA-mutated platinum-sensitive, relapsed high-grade epithelial ovarian cancer can be a devastating diagnosis for patients and their families as it often has a poor prognosis. This recommendation is an important milestone in advancing cancer care in the UK. We are optimistic that this treatment option may help improve outcomes for patients.”